Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991536 | 0.94 | ALDH1A1 (0.39) | ACE2ALDH1A1NAAAHRH4HRH3 | |
| SCHEMBL9617577 | 0.92 | ACE2 (0.35) | ACE2ALDH1A1NAAAHRH4HRH3 | |
| SCHEMBL28418967 | 0.86 | TSHR (0.44) | ACE2ALDH1A1NAAAHRH4HRH3 | |
| SCHEMBL3088928 | 0.85 | ALDH1A1 (0.42) | ALDH1A1HRH4HRH3CA1CA2 | |
| SCHEMBL756657 | 0.84 | ALDH1A1 (0.52) | ACE2ALDH1A1NAAAEPHX1TSHR | |
| SCHEMBL368275 | 0.84 | ALDH1A1 (0.52) | ACE2ALDH1A1NAAAEPHX1TSHR | |
| SCHEMBL1301124 | 0.84 | ALDH1A1 (0.52) | ACE2ALDH1A1NAAAEPHX1TSHR | |
| SCHEMBL1301422 | 0.84 | ALDH1A1 (0.52) | ACE2ALDH1A1NAAAEPHX1TSHR | |
| SCHEMBL20377653 | 0.84 | ALDH1A1 (0.52) | ACE2ALDH1A1NAAAEPHX1TSHR | |
| SCHEMBL1301841 | 0.84 | ALDH1A1 (0.52) | ACE2ALDH1A1NAAAEPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130144080-A1 | PROCESS FOR OBTAINING A DIALKYL CARBONATE AND AN ALKYLENE GLYCOL | BASF SE (DE) | 2013-06-06 | — | — | US | disclosed |
| EP-2167014-A2 | SILICONE-ORGANIC GELS WITH POLYALKYLOXYLENE CROSSLINKED SILICONE ELASTOMERS | Dow Corning Corporation (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009006091-A2 | SILICONE-ORGANIC GELS WITH POLYALKYLOXYLENE CROSSLINKED SILICONE ELASTOMERS | DOW CORNING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144080-A1 | PROCESS FOR OBTAINING A DIALKYL CARBONATE AND AN ALKYLENE GLYCOL | AGL, GNE, ADH1C | ACE2 2024/4885ALDH1A1 2328/4885NAAA 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.